Overview

Initial Treatment With Bevacizumab in Choroidal Neovascularization Associated to High Myopia

Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this protocol is to determine wether the initial protocol in the treatment of subfoveal choroidal neovascularization associated to High Myopia with bevacizumab intravitreal injections is more effective when using 3 doses vs using 1 single dose in the load period
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA
Treatments:
Bevacizumab
Criteria
Inclusion Criteria:

- Active subfoveal/juxtafoveal choroidal neovascularization in high myopia confirmed by
Fundus Fluorescein angiography and Optical Coherence Tomography

- Best corrected visual acuity loss with less than 6 months of evolution, caused mainly
by the neovascular lesion (based in investigator´s criteria)

- No atrophy or fibrotic component that may prevent visual acuity improvement

- Patients previously treated with Photodynamic Therapy are allowed to participate in
this study

- Signed informed consent

- Signed data protection consent

- Negative pregnancy test in potential childbearing women at screening, with accepted
contraceptive method during the whole study

Exclusion Criteria:

- Previous vitreous surgery in study eye

- Tractional maculopathy or epiretinal membrane found in Optical Coherence Tomography

- Media opacities that may prevent correct fundus assessment

- Lack of posterior capsule integrity in pseudophakic patients

- Patients with great possibilities of not being able to attend to study visits / follow
visit procedures (investigator´s criteria)

- Patients previously treated with intravitreal antiangiogenic injections